Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis

Mei Xiang1, Pi-Xiao Wang2, Ai-Bing Wang3

  • 1Department of Cardiology, The Central Hospital of Wuhan, Wuhan, China; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Animal Experiment Center/Animal Biosafety Level-III Laboratory, Wuhan University, Wuhan 430060, China.

Journal of Hepatology
|February 11, 2016
PubMed
Abstract

Insights

Tumor necrosis factor receptor-associated factor 1 (TRAF1) promotes liver fat accumulation and insulin resistance. Inhibiting TRAF1 may offer a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD) and metabolic disorders.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Metabolic Disorders

Background:

  • Tumor necrosis factor receptor-associated factor 1 (TRAF1) is an adapter protein involved in immunity and cell death.
  • The role of TRAF1 in hepatic steatosis and related metabolic disorders, despite its link to inflammation and insulin dysfunction, remains unclear.

Purpose of the Study:

  • To investigate the role of TRAF1 in the development of hepatic steatosis and associated metabolic disorders.
  • To elucidate the molecular mechanisms by which TRAF1 influences insulin resistance, inflammation, and lipid accumulation in the liver.

Main Methods:

  • Evaluation of TRAF1's role in high-fat diet-induced and genetic obesity models.
  • Utilizing global TRAF1 knockout and liver-specific TRAF1 overexpression mice for phenotypic examinations.
  • In vivo and in vitro studies to explore molecular mechanisms.

Main Results:

  • TRAF1 expression is upregulated in NAFLD patients, obese mice, and palmitate-treated hepatocytes.
  • TRAF1 deficiency showed hepatoprotective effects, while its overexpression exacerbated insulin resistance, inflammation, and hepatic steatosis.
  • TRAF1 promotes hepatic steatosis by activating the ASK1-mediated P38/JNK pathway.

Conclusions:

  • TRAF1 acts as a positive regulator in insulin resistance, inflammation, and hepatic steatosis.
  • This regulation is dependent on the activation of the ASK1-P38/JNK axis.
  • Targeting TRAF1 may be a potential therapeutic approach for metabolic liver diseases.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K